Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CVL-751 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| CVL-751 | DRUG | Oral tablet |
CVL-751 is an investigational small molecule being developed for the treatment of Parkinson Disease. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. A completed Phase 1 trial evaluated its use in subjects with Parkinson Disease.
CVL-751 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The company is conducting clinical research to evaluate the safety and tolerability of this investigational therapy for Parkinson Disease.
CVL-751 is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. A Phase 1 trial has been completed, and the drug remains in early-stage clinical research for Parkinson Disease.
CVL-751 has one completed Phase 1 clinical trial registered under NCT04295642, titled "A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease." The trial enrolled 24 participants and was an uncontrolled, non-randomized, open-label study.
No, CVL-751 is not FDA approved. It is an investigational small molecule in Phase 1 clinical development for Parkinson Disease. The drug has not completed the clinical trials and regulatory review process required for marketing approval.